Navigation Links
Watson to Present at the Bank of America Merrill Lynch 2012 Health Care Conference

PARSIPPANY, N.J., May 4, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty global pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business at the Bank of America Merrill Lynch 2012 Healthcare Conference on Wednesday, May 16, 2012 at 10:00 AM Pacific Time at the Encore at the Wynn in Las Vegas, Nevada. The presentation will be webcast live and can be accessed on Watson Pharmaceuticals' Investor Relations Website at The webcast can also be accessed at the following URL:

An archived version will be available approximately one hour after the live presentation ends and can be accessed at the same locations for 90 days.

About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. The Company is also developing biosimilar products in Women's Health and Oncology. Additionally, Watson distributes generic and branded pharmaceuticals through its Anda, Inc. distribution business. Watson has operations in many of the worlds established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at CONTACTS: Investors:Lisa DeFrancesco (862) 261-7152Media:Charlie Mayr(862) 261-8030(Photo:


SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
3. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
4. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
5. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
6. Watson and Barr Settle Lawsuit Over Oxytrol(R)
7. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
8. Watson Completes Acquisition of Eden Biodesign
9. Watson to Present at Credit Suisse Healthcare Conference
10. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
11. Watson Files FDA Application for Generic Rozerem(R)
Post Your Comments:
(Date:12/1/2015)... -- CytRx Corporation (NASDAQ: CYTR ), a biopharmaceutical ... that it has reached its enrollment target of 400 ... trial of aldoxorubicin in patients with previously treated soft ... in Q1 2016. The Phase 3 trial is a randomized, ... from the FDA at 79 sites in ...
(Date:12/1/2015)... Dec. 1, 2015  InCarda Therapeutics, Inc. (InCarda), a ... of therapies for cardiovascular conditions via the inhalation route, ... in Australia . InCarda is planning ... Australia in the first half of ... medical centers in Adelaide and ...
(Date:12/1/2015)... , Dec. 1, 2015  Booth #3506 – Claymount is ... the annual meeting of the Radiological Society of ... this year. Based in the Netherlands ... Varian Medical Systems (NYSE: VAR ) and is one ... chambers and solid state automatic exposure control systems for controlling ...
Breaking Medicine Technology:
(Date:12/1/2015)... , ... December 01, 2015 , ... ... 1980s we have seen vast improvements in scientific research and discoveries, leading us ... providing increased hope and relief to those affected by HIV/AIDS. Mediaplanet’s cross-platform edition ...
(Date:12/1/2015)... ... December 01, 2015 , ... The ... been lifted as IMAGE Information Systems launches MED-TAB™ -- the world’s first portable ... Meeting from November 29 to December 4, 2015. , MED-TAB is expected ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... must mark the film for accurate interpretation by the radiologist. The marking utensils ... inventor from Sacramento, Calif., has found a way to alleviate this problem. , ...
(Date:12/1/2015)... San Francisco, CA (PRWEB) , ... December 01, ... ... The Behavioral Health Center of Excellence (BHCOE) today announced that the organization has ... based in San Francisco, with a Distinguished Award. The award celebrates exceptional special ...
(Date:12/1/2015)... ... ... Lutronic, a leading innovator of aesthetic and medical laser and energy-based technology, ... in the United States. Clarity is a Superior Dual Wavelength Platform which combines ... single platform that is easy to own and operate. , For over a ...
Breaking Medicine News(10 mins):